The colours of amphetamine-induced cardiomyopathy

Bostjan Berlot^{1

2

3}, Matthew G L Williams^{1

2}, Chiara Bucciarelli-Ducci^{1

2}

Affiliations

¹ Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) Biomedical Research Centre, University Hospitals Bristol NHS Trust and University of Bristol.
² Bristol Medical School, University of Bristol, Bristol, UK.
³ Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Case Reports

Bostjan Berlot et al. J Cardiovasc Med (Hagerstown). 2020 May.

. 2020 May;21(5):396-397.

doi: 10.2459/JCM.0000000000000922.

Bostjan Berlot^{1

2

3}, Matthew G L Williams^{1

2}, Chiara Bucciarelli-Ducci^{1

2}

¹ Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) Biomedical Research Centre, University Hospitals Bristol NHS Trust and University of Bristol.
² Bristol Medical School, University of Bristol, Bristol, UK.
³ Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

No abstract available

References

1. Paratz ED, Cunningham NJ, MacIsaac AI. The cardiac complications of methamphetamines. Hear Lung Circ 2016; 25:325–332.
1. Voskoboinik A, Ihle JF, Bloom JE, Kaye DM. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J 2016; 46:723–727.
1. Schürer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R, et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Hear Fail 2017; 5:435L–445.